Trial Profile
A Single-blind, Intra-individual, Crossover, Multicenter Study of the Efficacy, Safety and Tolerability of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent in the Enhanced Magnetic Resonance Angiography (MRA) in Chinese Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gadobutrol (Primary) ; Gadopentetic acid
- Indications Vascular disorders
- Focus Diagnostic use
- Sponsors Bayer
- 11 May 2014 New trial record